首页> 外文期刊>Therapeutic Drug Monitoring >NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation.
【24h】

NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation.

机译:从心脏移植后的常规药物监测数据中得出口服环孢菌素的NONMEM群体药代动力学模型。

获取原文
获取原文并翻译 | 示例
       

摘要

The population pharmacokinetics of cyclosporine (CsA) in adult recipients of cardiac transplants were determined from sparse, retrospective drug monitoring data accumulated for at least 3 months after surgery. All were receiving oral CsA twice daily, and morning trough levels in whole-blood were measured by high-performance liquid chromatography. Additional data included height, weight, gender, age, ethnicity, hematocrit, total bilirubin, and concurrent drug use. Population modeling was performed using NONMEM on 36 randomly selected patients, assuming a one-compartment model with first-order absorption and elimination. Improved fits were obtained by incorporating the following expression in the model to adjust oral bioavailability as a function of postoperative day (POD): F = 0.2 + 10 x ABS (POD - 7)/([POD + 10] x 60). Interpatient variability (CV%) in clearance (CL) was 20.2%. There was a mean bias of 8.5% at the average CsA concentration of 250 ng/ml when the predictive performance was assessed statistically in a reserved subset of 33 patients who received cardiac transplants. For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration. These results compared favorably with those reported elsewhere for studies of postcardiac transplant kinetics using the traditional multiple blood sampling approach.
机译:根据术后至少3个月内收集的稀疏回顾性药物监测数据,确定了心脏移植成人接受者中环孢素(CsA)的总体药代动力学。所有患者每天接受两次口服CsA,并通过高效液相色谱法测定全血中的晨谷水平。其他数据包括身高,体重,性别,年龄,种族,血细胞比容,总胆红素和同时使用药物。使用NONMEM对36位随机选择的患者进行人口建模,并假设其具有一阶吸收和消除的单室模型。通过在模型中纳入以下表达式来调整术后口服生物利用度,以提高术后适应性(POD):F = 0.2 + 10 x ABS(POD-7)/([POD + 10] x 60)。清除率(CL)的患者间差异(CV%)为20.2%。当对33例接受心脏移植的患者的保留子集进行统计学评估时,平均CsA浓度为250 ng / ml时,平均偏差为8.5%。对于整个人群(n = 69位患者),平均CsA CL和终末半衰期(T1 / 2)分别为:CL(l / h)= 0.256 x体重(kg); T1 / 2 = 11.0小时,或CL(l / h)= 0.184 x重量(kg);如果同时使用地尔硫卓,则T1 / 2 = 14.7小时。这些结果与其他使用传统的多采血方法进行的明信片移植动力学研究中报道的结果相比具有优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号